The global economic burden of asthma and chronic obstructive pulmonary disease

Abstract

Non-communicable diseases are now the number one cause of disabilities and loss of life expectancy. Among them, chronic respiratory conditions constitute a major class. The burden of chronic respiratory diseases is generally increasing across the globe, and asthma and chronic obstructive pulmonary disease (COPD) are among the main causes of mortality and morbidity. However, the direct and indirect costs of these conditions vary across jurisdictions. This article reports on recent estimates of the costs of asthma and COPD, with a focus on comparing disease burden across different regions. Overall, there is tremendous variation in per capita annual costs of asthma and COPD. However, the methodology of the cost-of-illness studies is also vastly different, making it difficult to associate differences in reported costs to differences in the true burden of asthma and COPD. Suggestions are provided towards improving the validity and comparability of future studies.

A systematic review of the effectiveness of discharge care bundles for patients with COPD

“…In particular, COPD places a major burden on health systems1 and greatly impacts patients' health status2 and quality of life (QoL) 3. The progressive nature of COPD and predisposition to exacerbations results in frequent healthcare encounters, emergency department (ED) visits and hospital admissions.…”

A Real-World Study of 30-Day Exacerbation Outcomes in Chronic Obstructive Pulmonary Disease (COPD) Patients Managed with Aerobika OPEP

“…The biggest driver of these healthcare costs is hospitalization [1]. COPD affects approximately 5% of the US adult population and is often associated with exacerbations [2][3][4].…”

Transforming Growth Factor β1 Function in Airway Remodeling and Hyperresponsiveness. The Missing Link?

“…Approximately 50% of patients with asthma, however, experience inadequate control with current therapeutics (4). Because of the increasing prevalence and per-patient costs of asthma (5), an urgent need exists to determine therapeutic targets to reduce asthma-related morbidity.…”